Cargando…

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations

PURPOSE: With the broad use of next-generation sequencing assays, it has become clear that mutations in DNA repair genes are more commonly found than previously reported. In advanced prostate cancer patients with BRCA1/2 or ATM mutations, poly (ADP-ribose) polymerase inhibition (PARPi) causes an inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Werdt, Alexander, Brandt, Laura, Schärer, Orlando D., Rubin, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547927/ https://www.ncbi.nlm.nih.gov/pubmed/34712892 http://dx.doi.org/10.1200/PO.21.00152

Ejemplares similares

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

Alterations in homologous recombination repair genes in prostate cancer brain metastases
por: Rodriguez-Calero, Antonio, et al.
Publicado: (2022)

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
por: Yadav, Anjali, et al.
Publicado: (2023)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
por: Pai Bellare, Ganesh, et al.
Publicado: (2021)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors
por: Peng, Yihan, et al.
Publicado: (2019)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
por: Gundogdu, Ramazan, et al.
Publicado: (2021)

Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
por: Hou, Dong, et al.
Publicado: (2017)

LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repair
por: Chen, Lifeng, et al.
Publicado: (2021)

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair
por: Kong, Yangyang, et al.
Publicado: (2022)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
por: Dang, Tuyen T., et al.
Publicado: (2021)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer
por: Mansour, W. Y., et al.
Publicado: (2018)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines
por: Wikiniyadhanee, Rakkreat, et al.
Publicado: (2023)

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
por: Amin, Oreekha, et al.
Publicado: (2015)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer
por: Gonzalez, David, et al.
Publicado: (2021)

Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
por: Wang, Zhihai, et al.
Publicado: (2019)

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018)

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients
por: Liu, Yixiao, et al.
Publicado: (2023)

Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes
por: Riaz, Nadeem, et al.
Publicado: (2017)

Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer
por: André, Saudade, et al.
Publicado: (2020)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors
por: Miller, Rowan E, et al.
Publicado: (2022)

Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic
por: Cimadamore, Alessia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a860rgftomlhh5735nrmm04b6o